Trials / Completed
CompletedNCT01936870
Drug Use Investigation for Toviaz
DRUG USE INVESTIGATION FOR TOVIAZ
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 2,521 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to collect effectiveness and safety information of fesoterodine related to their appropriate use in daily practice.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Fesoterodine (Toviaz) | Fesoterodine 4 mg or 8 mg orally. Toviaz will be dosed according to labeling. The administration and duration of therapy will be determined by the treating physician to meet the patient's needs for treatment. |
Timeline
- Start date
- 2013-10-01
- Primary completion
- 2016-05-19
- Completion
- 2016-05-19
- First posted
- 2013-09-06
- Last updated
- 2021-06-11
- Results posted
- 2017-04-07
Source: ClinicalTrials.gov record NCT01936870. Inclusion in this directory is not an endorsement.